A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

Feng Wang, Rui‐Hua Xu, Fuxiang Zhou et al.|Journal of Clinical Oncology|2020

Cited by 2